IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: PSC who wrote (1679)	7/28/1999 5:14:00 PM
From: Maurice Winn	1 Recommendation Read Replies (1) of 1762

Thanks for the comments. To be blunt, the truthfulness of the cases of tuberculosis seems questionable. Since it was a 'top' doctor who told me that the cases occurred, I took it seriously. Nobody else finds tuberculosis in 2 out of very few treatment cases. Hence my question on urls to treatment side effects. Rituxan surely adds to the normal immunodeficiency associated with lymphoma because it skittles nearly all the B-cells, leaving a person vulnerable to tuberculosis and other opportunistic infections. Meanwhile IDEC reached $100 for the first time today, reflecting serious success in treatment of low grade CD20 positive B-cell Non Hodgkins Lymphoma. Congratulations IDEC on medical and financial success! Maurice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next